Table 3.
Summary of indirect statistical comparisons between dalteparin and enoxaparin using the method of Bucher et al., (1997)
| Comparison | RR: E vs. D | (95%CI) | P-Value |
|---|---|---|---|
| THR Patients: Placebo Trials | |||
| VTE | 1.26 | (0.85 - 1.88) | 0.78 |
| Major Bleeds | 2.57 | (0.22 - 29.8) | 0.58 |
| Thrombocytopenia | 2.34 | (0.22 - 24.4) | 0.69 |
| Death | 0.80 | (0.06 - 1.0) | 0.90 |
| THR Patients: UH Trials | |||
| VTE | 1.30 | (0.42 - 4.1) | 0.49 |
| Major Bleeds | NA | ||
| Thrombocytopenia | 0.57 | (0.03 - 11.4) | 0.94 |
| Death | NA | (0.03 - 17.9) | 0.94 |
Abbreviations: RR = relative risk, D = dalteparin, E = enoxaparin, P = placebo, UH = unfractionated heparin, THR = total hip replacement, VTE = venous thromboembolic events, NA = data not available for calculation